Summary:
78 Week, Phase 2, Double-Blind, Safety and Efficacy Study for Moderate to Severe Rheumatiod Arthritis.
- Participants Must Be 18- 75 Years of Age.
- Body Mass Index Below 40.
- Participants Must Have 6 Swollen and Tender Joints.
- Participants Must Be on a Stable Dose of Methotrexate for 4 Weeks.
Qualified Participants May Receive:
- Study Related Medication
- Study Related Medical Care
- Compensation for Time and Travel